

10572267

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1 JUN 01 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 JUN 01 CAS REGISTRY Source of Registration (SR) searching enhanced on STN

NEWS 4 JUN 26 NUTRACEUT and PHARMAML no longer updated
NEWS 5 JUN 29 IMSCOPROFILE now reloaded monthly
NEWS 6 JUN 29 EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS 7 JUL 09 PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 8 JUL 14 USGENE enhances coverage of patent sequence location (PSL) data
NEWS 9 JUL 27 CA/Caplus enhanced with new citing references
NEWS 10 JUL 16 GBFULL adds patent backfile data to 1855
NEWS 11 JUL 21 USGENE adds bibliographic and sequence information
NEWS 12 JUL 28 EPFULL adds first-page images and applicant-cited references
NEWS 13 JUL 28 INPADOCDB and INPAFAMDB add Russian legal status data
NEWS 14 AUG 08 Improve STN by completing a survey and be entered to win a gift card
NEWS 15 AUG 10 Time limit for inactive STN sessions doubles to 40 minutes

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

10576267c.trn

08/10/2009

Page 1

10572267

```
* Please take a couple of minutes to complete our short survey. Your *
* name will be entered to win one of five $20 Amazon.com gift cards. *
*
* See NEWS 14 for details or go directly to the survey at: *
* http://www.zoomerang.com/Survey/?p=WEB229H4S8Q5UL *
*
*****
```

* *

FILE 'HOME' ENTERED AT 15:13:02 ON 10 AUG 2009

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.22 | 0.22 |

FILE 'REGISTRY' ENTERED AT 15:13:18 ON 10 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2009 HIGHEST RN 1173690-68-0
DICTIONARY FILE UPDATES: 9 AUG 2009 HIGHEST RN 1173690-68-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10576267c.str



chain nodes :
 12 15 16 17
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11
 chain bonds :
 5-12 7-12 11-15 15-16 15-17
 ring bonds :
 1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
 exact/norm bonds :
 3-4 4-5 5-12 7-12 15-16 15-17
 exact bonds :
 1-2 1-5 2-3 11-15
 normalized bonds :
 6-7 6-11 7-8 8-9 9-10 10-11
 isolated ring systems :
 containing 1 : 6 :

G1:A,Ak,NH,CO2H

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d 11
 L1 HAS NO ANSWERS
 L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>
 Uploading C:\Program Files\Stnexp\Queries\19576267d.str



10572267


chain nodes :
12 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
5-12 7-12 11-15 15-16 15-17
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
3-4 4-5 5-12 7-12 15-16 15-17
exact bonds :
1-2 1-5 2-3 11-15
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :

G1:A,Ak,NH,CO2H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 15:CLASS 16:CLASS 17:CLASS

L2 STRUCTURE UPLOADED

=> d 12
L2 HAS NO ANSWERS
L2 STR



G1 A,Ak,NH,CO2H

Structure attributes must be viewed using STN Express query preparation.

=> s 12
SAMPLE SEARCH INITIATED 15:15:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 58 TO ITERATE

100.0% PROCESSED 58 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 704 TO 1616
PROJECTED ANSWERS: 3 TO 163

10572267

L3 3 SEA SSS SAM L2

=> s 12 sss full
FULL SEARCH INITIATED 15:15:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED = 953 TO ITERATE

100.0% PROCESSED 953 ITERATIONS 14 ANSWERS
SEARCH TIME: 00.00.01

L4 14 SEA SSS FUL L2

| | SINCE FILE | TOTAL |
|----------------------|------------|---------|
| => FIL HCAPLUS | ENTRY | SESSION |
| COST IN U.S. DOLLARS | | |
| FULL ESTIMATED COST | 186.84 | 187.06 |

FILE 'HCAPLUS' ENTERED AT 15:15:12 ON 10 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Aug 2009 VOL 151 ISS 7
FILE LAST UPDATED: 9 Aug 2009 (20090809/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCPlus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s 14
L5 4 L4


=> d 15 ibib abs hitstr tot

L5 ANSWER 1 OF 4 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 20071259908 HCPLUS
 DOCUMENT NUMBER: 146:309313
 TITLE: Use of aminoarylthiazole and aminoaryloxazole dual c-kit/FGFR3 inhibitors for treating multiple myeloma
 INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre
 PATENT ASSIGNEE(S): Ab Science, Fr.
 SOURCE: PCT Int. Appl., 31pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2007026251 | A2 | 20070308 | WO 2006-IB3111 | 20060713 |
| WO 2007026251 | A3 | 20070712 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JE, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| EP 1904065 | A2 | 20080402 | EP 2006-820848 | 20060713 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| US 20080207572 | A1 | 20080828 | US 2008-995592 | 20080114 |
| PRIORITY APPLN. INFO.: | | | US 2005-698937P | P 20050714 |
| | | | WO 2006-IB3111 | W 20060713 |

OTHER SOURCE(S): MARPAT 146:309313
 AB The invention relates to a method for treating Multiple Myeloma, FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual c-kit/FGFR3 inhibitor, e.g. 2-aminoarylthiazoles and 2-aminoaryloxazoles.
 IT 928298-12-8 928298-16-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aminoarylthiazole and aminoaryloxazole dual c-kit/FGFR3 inhibitors for treatment of multiple myeloma)
 RN 928298-12-8 HCPLUS
 CN Benzamide, N-(3-chlorophenyl)-4-methyl-3-[(5-(4-pyridinyl)-2-oxazolyl)amino]- (CA INDEX NAME)

10572267




RN 928298-16-2 HCPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11 β ,16 α)-, mixt. with N-(3-chlorophenyl)-4-methyl-3-[[(5-(4-pyridinyl)-2-oxazolyl]amino]benzamide (CA INDEX NAME)

CM 1

CRN 928298-12-8

CMF C22 H17 Cl N4 O2




CM 2

CRN 50-02-2

CMF C22 H29 F 05



Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 2 OF 4 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:395287 HCPLUS
 DOCUMENT NUMBER: 142:447205
 TITLE: Preparation of 2-(arylamino)oxazole derivatives as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3
 INVENTOR(S): Moussy, Alain; Wermuth, Camille; Grierson, David; Benjahad, Abdellah; Croisy, Martine; Ciufolini, Marco; Giethien, Bruno
 PATENT ASSIGNEE(S): Science AB, Fr.; Centre National de la Recherche Scientifique CNRS; Institut Curie
 SOURCE: PCT Int. Appl., 70 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|--|------------|
| WO 2005040139 | A2 | 20050506 | WO 2004-IB3698 | 20041022 |
| WO 2005040139 | A3 | 20051013 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004283162 | A1 | 20050506 | AU 2004-283162 | 20041022 |
| CA 2542909 | A1 | 20050506 | CA 2004-2542909 | 20041022 |
| EP 1684750 | A2 | 20060802 | EP 2004-791783 | 20041022 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| BR 2004015467 | A | 20061219 | BR 2004-15467 | 20041022 |
| JP 2007509130 | T | 20070412 | JP 2006-536215 | 20041022 |
| CN 1950347 | A | 20070418 | CN 2004-80037159 | 20041022 |
| US 20070142390 | A1 | 20070621 | US 2006-576267 | 20060418 |
| IN 2006DN02206 | A | 20070420 | IN 2006-DN2206 | 20060421 |
| MX 2006004581 | A | 20061120 | MX 2006-4581 | 20060424 |
| ZA 2006004041 | A | 20070425 | ZA 2006-4041 | 20060519 |
| NO 2006002308 | A | 20060522 | NO 2006-2308 | 20060522 |
| KR 2006118500 | A | 20061123 | KR 2006-710034 | 20060523 |
| PRIORITY APPLN. INFO.: | | | US 2003-513214P | P 20031023 |
| | | | WO 2004-IB3698 | W 20041022 |
| OTHER SOURCE(S): GI | | | CASREACT 142:447205; MARPAT 142:447205 | |



AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyloxy, etc.; R5 = H, (un)substituted linear or branched alkyl, COR8, etc.; R6 and R7 independently = H, halo, (un)substituted aryl, etc.; R8 = (un)substituted-aryl, -alkyl, -heteroaryl, etc.; R9 and/or R10 = H, (un)substituted-alkyl, -aryl, etc.; X = (un)substituted-alkyl, C:OY, NR9R10, etc.; Y = NR9R10, NHR9R10, (un)substituted-aryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. Thus, e.g., 3-acetyl-pyridine was brominated and subsequently converted into the azido derivative, which was cyclized with 2-methyl-5-nitrophenyl isocyanate followed by a reduction to the resp. amine derivative, which could be further elaborated to


give II. The activity of I was evaluated in tyrosine kinase inhibition assays and it revealed that selected compds. of the invention possessed IC₅₀ values of less than 1 μ M. I should prove useful in the treatment of neoplastic diseases. Pharmaceutical compns. comprising I are disclosed.

IT 851318-26-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3)

RN 851318-26-8 HCAPLUS

CN Benzamide, N-(4-cyanophenyl)-4-methyl-3-[(5-(3-pyridinyl)-2-oxazolyl)amino]- (CA INDEX NAME)




IT 851318-27-9P 851318-28-0P 851318-29-1P
851318-30-4P 851318-31-5P 851318-32-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3)


RN 851318-27-9 HCPLUS

CN Benzamide, N-[3-(dimethylamino)phenyl]-4-methyl-3-[(5-(4-pyridinyl)-2-oxazolyl]amino]- (CA INDEX NAME)



RN 851318-28-0 HCPLUS


CN Benzamide, N-[2-(dimethylamino)ethyl]-4-methyl-3-[(5-(3-pyridinyl)-2-oxazolyl]amino]- (CA INDEX NAME)



RN 851318-29-1 HCPLUS


CN Benzamide, N-(3-fluoro-4-methylphenyl)-4-methyl-3-[(5-(4-pyridinyl)-2-

oxazolyl]amino]- (CA INDEX NAME)




RN 851318-30-4 HCPLUS

CN Benzamide, N-(3-chlorophenyl)-4-methyl-3-[(5-(3-pyridinyl)-2-oxazolyl)amino]- (CA INDEX NAME)




RN 851318-31-5 HCPLUS

CN Benzamide, 4-methyl-N-(phenylmethyl)-3-[(5-(4-pyridinyl)-2-oxazolyl)amino]- (CA INDEX NAME)



RN 851318-32-6 HCPLUS

CN Benzamide, N-[(4-methoxyphenyl)methyl]-4-methyl-3-[(5-(4-pyridinyl)-2-oxazolyl)amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1082034 HCAPLUS
DOCUMENT NUMBER: 142:56293
TITLE: P-38 inhibitors
INVENTOR(S): Dong, Qing; Pierre, Fabrice; Wang, Jianqiang
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 76 pp.
CODEN: USXECO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|------------|
| US 20040254236 | A1 | 20041216 | US 2004-860768 | 20040602 |
| AU 2004251668 | A1 | 20050106 | AU 2004-251668 | 20040602 |
| AU 2004251668 | B2 | 20080320 | | |
| CA 2528438 | A1 | 20050106 | CA 2004-2528438 | 20040602 |
| WO 2005000298 | A2 | 20050106 | WO 2004-US17580 | 20040602 |
| WO 2005000298 | A3 | 20050303 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| EP 1635824 | A2 | 20060322 | EP 2004-754233 | 20040602 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| BR 2004010905 | A | 20060627 | BR 2004-10905 | 20040602 |
| CN 1829513 | A | 20060906 | CN 2004-80021972 | 20040602 |
| JP 2006526656 | T | 20061124 | JP 2006-515154 | 20040602 |
| MX 2005013075 | A | 20060317 | MX 2005-13075 | 20051202 |
| IN 2005CN03236 | A | 20070914 | IN 2005-CN3236 | 20051202 |
| PRIORITY APPLN. INFO.: | | | US 2003-475662P | P 20030603 |

US 2003-531541P P 20031219
 WO 2004-US17580 W 20040602

OTHER SOURCE(S) :
 GI

MARPAT 142:56293



AB 5-Membered heterocycle-based p38 kinase inhibitors I (R1 = H, Me, halogen, OH, lower alkyl, lower cycloalkyl, lower alkynyl, CF3, OMe, OCF3, CN, NH2, alkylamine, alkoxy; R2 = alkyl, substituted alkyl, lower cycloalkyl, halo, CF3, OCF3, alkoxy, alkylamine, sulfonyl, sulfone, amide, and n = 0, 1, or 2; R3 = H, alkyl, alkoxy, substituted alkyl, cycloalkyl, heteroaryl, heterocycle; Y = a single bond, C(O)NH, NHC(O), NHC(O)NH, SO2NH, NHSO2, C(O); B = a 5-membered heterocyclic ring system optionally substituted; Q = a single bond, O, S, alkylamine, SO, SO2, C(O), CO(O), C(O)NH, CH2; D = a monocyclic or bicyclic ring system) are prepared for the treatment of inflammatory and autoimmune diseases. Thus, to 3-amino-N-methoxy-4-methyl-benzamide in CH2Cl2 was added benzoyl isothiocyanate, and N, N-diisopropylethylamine followed by treatment with hydrazine monohydrate to give II. II had an IC50 of less than 50 nM against p38 α .


IT 808737-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of p-38 kinase inhibitors for the treatment of inflammatory and autoimmune diseases)

RN 808737-97-5 HCPLUS

CN Benzanide, N-cyclopropyl-4-methyl-3-[(5-phenyl-2-oxazolyl)amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)



L5 ANSWER 4 OF 4 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:755249 HCPLUS

DOCUMENT NUMBER: 137:263025
 TITLE: Preparation of substituted oxazoles as IMPDH inhibitors
 INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi, Gregory S.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 428,432.
 CODEN: USXKC0
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-----------------|-----------------|----------|
| US 20020143176 | A1 | 20021003 | US 2001-997963 | 20011129 |
| US 6596747 | B2 | 20030722 | | |
| US 6399773 | B1 | 20020604 | US 1999-428432 | 19991027 |
| WO 2003047512 | A2 | 20030612 | WO 2002-US38038 | 20021127 |
| WO 2003047512 | A3 | 20031016 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2002352950 | A1 | 20030617 | AU 2002-352950 | 20021127 |
| EP 1448187 | A2 | 20040825 | EP 2002-789910 | 20021127 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 1998-106186P | P 19981029 | |
| | | US 1999-428432 | A2 19991027 | |
| | | US 2001-997963 | A 20011129 | |
| | | WO 2002-US38038 | W 20021127 | |

OTHER SOURCE(S): MARPAT 137:263025

GI




AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R3, R4; R3 = 5-6-membered (un)saturated heterocyclic ring; R4 = H, halo, NO, CF₃, alkyl, alkoxy, etc.; R = H, alkyl; R1-2 = H, halo, NO₂, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared 5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph cyanocarbonimidate (CH₃CN, reflux, 40 h) to give an intermediate which was reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors of IMPDH enzyme and/or serine protease factor VIIa.

IT 463941-53-9P, 3-[5-[2-[(2-Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]-N-methylbenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IMPDH inhibitor; preparation of substituted oxazoles as IMPDH inhibitors)

RN 463941-53-9 HCPLUS

CN Benzamide, 3-[[5-[2-[(3-amino-2-oxopropyl)amino]methyl]phenyl]-2-oxazolyl]amino]-N-methyl-



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS

10572267

RECORD (12 CITINGS)

| | | |
|--|------------|---------|
| => log y | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| FULL ESTIMATED COST | ENTRY | SESSION |
| | 36.81 | 223.87 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| CA SUBSCRIBER PRICE | ENTRY | SESSION |
| | -3.28 | -3.28 |

STN INTERNATIONAL LOGOFF AT 15:18:09 ON 10 AUG 2009